Q2 2024 EPS Estimates for Sarepta Therapeutics, Inc. Lowered by Analyst (NASDAQ:SRPT)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) – Equities researchers at Leerink Partnrs dropped their Q2 2024 earnings estimates for shares of Sarepta Therapeutics in a note issued to investors on Wednesday, May 1st. Leerink Partnrs analyst J. Schwartz now expects that the biotechnology company will post earnings per share of ($0.12) for the quarter, down from their previous forecast of $0.19. The consensus estimate for Sarepta Therapeutics’ current full-year earnings is $2.23 per share.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $0.73 earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.84. Sarepta Therapeutics had a net margin of 1.20% and a return on equity of 2.20%. The business had revenue of $413.50 million for the quarter, compared to analyst estimates of $375.52 million. During the same quarter last year, the firm earned ($1.44) EPS. Sarepta Therapeutics’s quarterly revenue was up 63.1% compared to the same quarter last year.

Other research analysts have also issued research reports about the stock. Wedbush reissued an “outperform” rating and set a $224.00 price objective on shares of Sarepta Therapeutics in a research note on Thursday, February 29th. Citigroup upped their price target on shares of Sarepta Therapeutics from $160.00 to $172.00 and gave the company a “buy” rating in a report on Thursday, February 29th. Needham & Company LLC reiterated a “buy” rating and issued a $166.00 price target on shares of Sarepta Therapeutics in a report on Thursday, May 2nd. JPMorgan Chase & Co. reduced their price target on shares of Sarepta Therapeutics from $177.00 to $175.00 and set an “overweight” rating for the company in a report on Friday, May 3rd. Finally, Evercore ISI upped their price target on shares of Sarepta Therapeutics from $108.00 to $138.00 and gave the company an “in-line” rating in a report on Tuesday, February 20th. Four investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $160.60.

Sarepta Therapeutics Stock Up 0.7 %

Sarepta Therapeutics stock opened at $136.04 on Monday. The company’s 50 day simple moving average is $125.47 and its 200 day simple moving average is $111.07. Sarepta Therapeutics has a fifty-two week low of $55.25 and a fifty-two week high of $159.89. The firm has a market capitalization of $12.86 billion, a price-to-earnings ratio of 1,236.73 and a beta of 0.95. The company has a debt-to-equity ratio of 1.18, a current ratio of 4.05 and a quick ratio of 3.44.

Hedge Funds Weigh In On Sarepta Therapeutics

Several large investors have recently modified their holdings of SRPT. Principal Securities Inc. bought a new position in shares of Sarepta Therapeutics in the fourth quarter valued at about $26,000. Mather Group LLC. acquired a new position in shares of Sarepta Therapeutics in the first quarter valued at about $28,000. Riggs Asset Managment Co. Inc. grew its stake in shares of Sarepta Therapeutics by 125.0% in the first quarter. Riggs Asset Managment Co. Inc. now owns 225 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 125 shares in the last quarter. Montag A & Associates Inc. acquired a new stake in Sarepta Therapeutics during the third quarter worth about $30,000. Finally, Cary Street Partners Investment Advisory LLC grew its stake in Sarepta Therapeutics by 154.0% during the third quarter. Cary Street Partners Investment Advisory LLC now owns 254 shares of the biotechnology company’s stock worth $31,000 after buying an additional 154 shares in the last quarter. 86.68% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Sarepta Therapeutics news, Director Stephen Mayo sold 3,135 shares of the company’s stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $122.96, for a total transaction of $385,479.60. Following the sale, the director now directly owns 6,621 shares of the company’s stock, valued at $814,118.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Sarepta Therapeutics news, Director Stephen Mayo sold 3,135 shares of the company’s stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $122.96, for a total transaction of $385,479.60. Following the sale, the director now directly owns 6,621 shares of the company’s stock, valued at $814,118.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Ian Michael Estepan sold 1,200 shares of the company’s stock in a transaction on Friday, March 1st. The stock was sold at an average price of $128.30, for a total transaction of $153,960.00. Following the sale, the chief financial officer now directly owns 39,114 shares in the company, valued at $5,018,326.20. The disclosure for this sale can be found here. Over the last three months, insiders have sold 25,731 shares of company stock valued at $3,248,319. 7.70% of the stock is currently owned by corporate insiders.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.